Meiji Yasuda Life Insurance Co Boosts Stock Holdings in Edwards Lifesciences Corporation $EW

Meiji Yasuda Life Insurance Co grew its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 39.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 24,900 shares of the medical research company’s stock after buying an additional 7,000 shares during the quarter. Meiji Yasuda Life Insurance Co’s holdings in Edwards Lifesciences were worth $2,252,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences during the 1st quarter valued at about $25,000. JPL Wealth Management LLC bought a new position in Edwards Lifesciences during the 3rd quarter worth approximately $25,000. MV Capital Management Inc. purchased a new position in Edwards Lifesciences in the 4th quarter worth approximately $26,000. RMG Wealth Management LLC purchased a new position in Edwards Lifesciences in the 1st quarter worth approximately $26,000. Finally, Pin Oak Investment Advisors Inc. purchased a new position in Edwards Lifesciences in the 2nd quarter worth approximately $26,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In related news, VP Annette Bruls sold 2,644 shares of Edwards Lifesciences stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the sale, the vice president owned 17,984 shares in the company, valued at $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 4,501 shares of company stock valued at $408,213 in the last ninety days. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Trading Up 0.3%

EW opened at $90.19 on Friday. The business has a 50 day simple moving average of $89.54 and a two-hundred day simple moving average of $85.03. The firm has a market capitalization of $51.93 billion, a price-to-earnings ratio of 51.83, a PEG ratio of 2.37 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business’s revenue was up 13.6% on a year-over-year basis. During the same quarter last year, the business posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of analyst reports. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $87.00 to $101.00 in a research note on Friday, July 24th. Piper Sandler reaffirmed an “overweight” rating and issued a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Royal Bank Of Canada upped their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Finally, Citigroup increased their price target on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.